Medicare beneficiaries with diabetes who are at the lowest levels of healthcare consumption often become some of the highest level consumers in subsequent years.
Among a working population, patients with asthma experienced significantly higher direct medical costs and modestly higher work loss than patients without asthma.
Integrated care systems allegedly provide better care. This study of 97 large medical groups nationally provides suggestive evidence that this may be true.
Offering a meal delivery service to patients in a community-based care transition program was associated with cost savings and a 38% lower 30-day hospital readmission rate.
Patients enrolled in the tuberculosis pay-for-performance program received more comprehensive ambulatory care with slightly lower costs and a higher treatment success rate.
In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.
A complex care management program implemented at 5 Next Generation accountable care organizations reduced all-cause inpatient admissions and total medical expenditures for participating beneficiaries.
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Current novel therapeutics for the prevention and treatment of bone loss in patients with inflammatory joint disease target cytokines and other inflammatory mediators. Mesenchymal stem cell therapy is a compelling new treatment currently being studied in clinical trials.
Hospitalization is costly and associated with the potential for adverse medical events. Hospitalists are uniquely positioned to help avoid unnecessary emergency department admissions through consultation.
Effective use of electronic medical record technology requires examination of the communication approaches of both care providers and patients.
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Lessons learned from implementation of a pharmacist-delivered medication therapy management intervention in primary care can inform future studies and be adopted into real-world clinical settings.